Delving into the Latest Updates on Impact Therapeutics Shanghai, Inc. with Synapse

概览

疾病领域	数量

肿瘤	1

排名前五的药物类型	数量

小分子化药	1

排名前五的靶点	数量

ATR(丝氨酸蛋白激酶ATR)	1

关联

1

项与 Impact Therapeutics Shanghai, Inc. 相关的药物

IMP-9064

靶点

ATR

作用机制

ATR抑制剂

在研机构

南京英派药业有限公司 [+2]

原研机构

上海瑛派药业有限公司

在研适应症

晚期恶性实体瘤 [+2]

非在研适应症-

最高研发阶段临床1/2期

首次获批国家/地区-

首次获批日期-

100 项与 Impact Therapeutics Shanghai, Inc. 相关的临床结果

登录后查看更多信息

0 项与 Impact Therapeutics Shanghai, Inc. 相关的专利（医药）

登录后查看更多信息

1

项与 Impact Therapeutics Shanghai, Inc. 相关的文献（医药）

2025-04-21·Cancer Research

Abstract 4203: Discovery and development of a potent and highly selective ATR inhibitor IMP9064

作者: Zhou, Ruiyu ; Cai, Sui Xiong ; Wang, Xiaozhu ; Tian, Ye Edward ; Jiang, Yangzhen ; Ma, Ning ; Guo, Mingchuan ; Chen, Mu

AbstractThe ataxia telangiectasia and RAD3-related (ATR) kinase is a crucial component of the DNA damage response (DDR) and functions in conjunction with ataxia telangiectasia mutated (ATM). Loss or functional deficiency of ATM may lead to increased reliance on ATR signaling pathways. Preclinical and clinical studies have indicated a potential synthetic lethality between ATR inhibition and ATM deficiency. We have identified a novel, potent, and highly selective ATR inhibitor IMP9064. Herein we present its discovery and IND enabling in vitro and in vivo studies. IMP9064 is highly activity inhibiting ATR, and is highly selective among kinases. IMP9064 also shows potent cytotoxicity to a wide range of cancer cell lines. In addition, IMP9064 has a desirable PK profile in preclinical species. IMP9064 has demonstrated anti-tumor efficacy in human colorectal cancer CDX animal models with good dose-response tumor growth inhibition and tolerability. The results of in vitro and in vivo studies suggest that used alone or in combination with PARP inhibitor, WEE1 inhibitor, PKMYT1 inhibitor or HER2 ADC, IMP9064 has good anti-tumor activity and synergistic effect. IMP9064 has entered a phase 1/2 study to evaluate the safety and efficacy either as monotherapy or in combination with PARP inhibitor Senaparib in patients with advanced solid tumors (ClinicalTrials.gov Identifier: NCT05269316). The recommended phase 2 dose (RP2D) has been determined and IMP9064 is currently in expansion studies for selected tumors.Citation Format:Sui Xiong Cai, Ning Ma, Xiaozhu Wang, Yangzhen Jiang, Mingchuan Guo, Ruiyu Zhou, Mu Chen, Ye Edward Tian. Discovery and development of a potent and highly selective ATR inhibitor IMP9064 [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 4203.

100 项与 Impact Therapeutics Shanghai, Inc. 相关的药物交易

登录后查看更多信息

100 项与 Impact Therapeutics Shanghai, Inc. 相关的转化医学

登录后查看更多信息